Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,548.00
Ask: 12,550.00
Change: 6.00 (0.05%)
Spread: 2.00 (0.016%)
Open: 12,570.00
High: 12,704.00
Low: 12,472.00
Prev. Close: 12,550.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BUZZ-U.S. Stocks on the Move-BlackBerry, AcelRx, Repros, Diamond Foods, Nike

Fri, 26th Sep 2014 12:35

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)

U.S. stock index futures were inching higher on Friday aftermajor indexes suffered their biggest drop since July, ahead ofdata on economic growth and consumer optimism.

Dow Jones industrial average futures were up 0.25percent at 16,942, S&P 500 futures were up 0.19 percentat 1,965.25 and Nasdaq 100 futures were up 0.24 percentat 4,017.

** BLACKBERRY LTD, Thursday close $9.8, +1.73 pctpremarket

The Canadian smartphone maker said itssecond-quarter loss narrowed to $207 million from $965 million ayear earlier in early sign turnaround efforts may be working.Still, revenue fell nearly 42 percent to $916 million, missingthe average analyst estimate of $949.63 million.

** ACELRX PHARMACEUTICALS INC, Thursday close$6.72, -17.71 pct premarket

The U.S. FDA said it would take another six months to reviewa marketing application on the drugmaker's recently rejectedpain management device.

** REPROS THERAPEUTICS INC, Thursday close $8.96,+11.61 pct premarket

The drug developer said its experimental drug to treat lowtestosterone, Androxal, met the main goal of late-stage study.

The U.S FDA has granted the company a pre-drug approvalmeeting to discuss Androxal in the first half of November.

** DIAMOND FOODS INC, Thursday close $26.62, +5.18pct premarket

The packaged food company reported better-than-expectedquarterly adjusted profit and sales, helped by higher demand forsnacks such as Pop Secret popcorn and Kettle potato chips.

** MICRON TECHNOLOGY INC, Thursday close $31.7, +6.91pct premarket

The memory chipmaker posted fiscal fourth-quarter resultsand gave a revenue outlook that impressed Wall Street as signsof stabilization in the personal computer industry supporteddemand for DRAM chips.

At least ten brokerages including Stifel Nicolaus andRaymond James raised their price targets on the stock.

** NIKE INC, Thursday close $79.75, +7.57 pctpremarket

The world's largest sportswear maker reported abetter-than-expected quarterly profit as it gains market sharein Europe and focuses on higher-margin products such as Flyknitsoccer boots.

Janney Capital Markets upgraded the stock to "buy" from"neutral" and at least 13 brokerages raised their price target.

** FINISH LINE INC, Thursday close $29.41, -10.06pct premarket

The footwear retailer posted a quarterly profit that missedWall Street's estimate, hurt by lower demand for basketballsporting goods. Its merchandise inventory increases 11.5percent.

** ALIBABA GROUP HOLDING LTD, Thursday close$88.92, +0.90 pct premarket

The newest way to bet on the fortunes of Chinese e-commerceheavyweight Alibaba will debut on Monday when its stock optionsgo live for trading, and investors should look for the initialaction to be very busy, but also choppy and potentially pricey.Options market traders say Alibaba puts and calls will likelysee heavy demand given the interest shown so far in the stocksince its record-setting $25 billion IPO last week.

** INTEL CORP Thursday close $34.14, +0.76 pctpremarket

Intel said it will pay as much as $1.5 billion for a 20percent stake in two mobile chipmakers with ties to the Chinesegovernment, in the hopes of catching up in a smartphone chipindustry dominated by rival Qualcomm Inc.

** APPLE INC, Thursday close $97.87, +0.92 pctpremarket

Apple broke its silence on complaints about bending iPhones,hours after withdrawing a glitch-ridden software update as thecompany struggles to restore momentum to the rollout of itslatest phones.

** ASTRAZENECA, Thursday close $70.99, +1.25 pctpremarket

The British pharmaceutical company said an expandeduse of its IRESSA treatment for lung cancer has been recommendedfor approval by European regulators. (Compiled by Shailaja Sharma in Bangalore; Editing by SavioD'Souza)

More News
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more
26 Dec 2023 21:26

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.